Your browser doesn't support javascript.
loading
Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer.
Lee, Erinna F; Fairlie, W Douglas.
Afiliação
  • Lee EF; La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.
  • Fairlie WD; Cell Death and Survival Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
Biochem Soc Trans ; 49(5): 2381-2395, 2021 11 01.
Article em En | MEDLINE | ID: mdl-34515749
ABSTRACT
The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives' mechanism(s)-of-action that provided the inspiration for what are now known as 'BH3-mimetics', the first clinically approved drugs designed to specifically inhibit protein-protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Proteínas Proto-Oncogênicas c-bcl-2 / Descoberta de Drogas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Proteínas Proto-Oncogênicas c-bcl-2 / Descoberta de Drogas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article